Abstract 112P
Background
Colorectal liver metastasis (CLM) is classified as Resectable, Unresectable, and Borderline resectable (BR) based on Technical and Oncological categories, with recommended treatments tailored to each classification. However, there is currently no appropriate classification for instances of liver recurrence in CLM (r-CLM).
Methods
This study evaluated patients with CLM who underwent initial liver resection between 2006 and 2020 and subsequently experienced liver recurrences. We investigated the long-term outcomes and prognostic factors related to r-CLM.
Results
Out of 949 cases of initial liver resection, 650 cases experienced recurrence, and among them, 392 cases were identified as r-CLM. Early recurrence within one year (er-CLM) exhibited significantly poorer overall survival (OS) compared to instances of r-CLM recurring after one year (p < 0.0001). Nonetheless, even within the er-CLM group, resected er-CLM showed notably improved prognosis in comparison to the non-resected group (5-year OS: 48.1% vs. 0%, p < 0.0001). Multivariate analysis of er-CLM identified independent prognostic factors as the number of recurrent tumors (≥ 4) (HR, 1.95; 95% CI, 1.24-3.07; p = 0.004), tumor size (≥ 5cm) (HR, 3.77; 95% CI, 1.46-9.76; p = 0.006), and presence of extrahepatic diseases (HR, 1.71; 95% CI, 1.09-2.71; p = 0.021). Stratifying these factors for recurrence-Resectable and recurrence-BR cases resulted in a significant difference in prognosis between the two groups (59.5% vs. 26.5%, p < 0.001).
Conclusions
Even in cases of early recurrence within one year, repeat liver resection contributes to extending prognosis. Regardless of the background at the initial liver resection, the number of r-CLM, tumor size, and presence of extrahepatic diseases were identified independent prognostic factors. Tailoring appropriate treatment based on the characteristics of recurrent tumors holds the potential to enhance the prognosis for r-CLM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract